title: Pretransplant positivity for circulating thyroid antibodies and graft survival in patients undergoing kidney transplant.
abstract: BACKGROUND
  Thyroid disturbances are common in kidney graft recipients and they may influence graft function. CXC chemokine ligand 10 plays a role in both autoimmune thyroiditis and graft rejection. Thyroid antibody (Ab) positivity has been regarded as a marker of imbalance of the immune system.
  
  
  OBJECTIVE
  To relate pretransplant positivity for antithyroperoxidase (TPO) Ab and antithyroglobulin (Tg) Ab with kidney graft outcome.
  
  
  METHODS
  Pretransplant thyroid antibodies were measured in 211 kidney graft recipients.
  
  
  RESULTS
  The 5-year death-censored graft survival rate was 91.5%. Pretransplant circulating Tg Ab and TPO Ab were detected in 12 (5.7%) and 13 (6.2%) patients, respectively. Lifetime analysis showed similar 5-year graft survival rates in patients negative or positive for Tg Ab and TPO Ab (91.5 vs. 91.7% for Tg Ab and 91.9 vs. 84.6% for TPO Ab). However, patients with pretransplant positivity for TPO Ab showed a significantly lower 5-year graft survival when early graft loss (12 months after transplant) was excluded (84.6 and 96.8% for TPO Ab+ and TPO Ab- patients, respectively; p < 0.05). Occurrence of acute rejection and chronic allograft nephropathy was unrelated to thyroid Ab positivity. Serum CXC chemokine ligand 10 levels were similar independent of Tg Ab and TPO Ab positivity.
  
  
  CONCLUSIONS
  Pretransplant positivity for TPO Ab may affect long-term graft survival in kidney graft recipients independent of occurrence of acute rejections and chronic allograft nephropathy.
authors.affiliation: Unit of Internal Medicine and Endocrinology Fondazione Salvatore Maugeri IRCCS, ISPESL Laboratory for Endocrine Disruptors, and Department of Endocrinology, University of Pavia, Pavia, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Rotondi
authors.forename: Paola
authors.initials: P
authors.lastname: Leporati
authors.forename: Sara
authors.initials: S
authors.lastname: Lodigiani
authors.forename: Giuseppe Stefano
authors.initials: GS
authors.lastname: Netti
authors.forename: Sara
authors.initials: S
authors.lastname: Precerutti
authors.forename: Flavia
authors.initials: F
authors.lastname: Magri
authors.forename: Alberto
authors.initials: A
authors.lastname: Rosati
authors.forename: Fabio
authors.initials: F
authors.lastname: Pradella
authors.forename: Maurizio
authors.initials: M
authors.lastname: Salvadori
authors.forename: Mario
authors.initials: M
authors.lastname: Serio
authors.forename: Paola
authors.initials: P
authors.lastname: Romagnani
authors.forename: Luca
authors.initials: L
authors.lastname: Chiovato
mesh_terms: D000208:Acute Disease; D000328:Adult; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D054357:Chemokine CXCL10 / Q000097:blood / Q000276:immunology; D002908:Chronic Disease; D018572:Disease-Free Survival; D005260:Female; D006084:Graft Rejection / Q000097:blood* / Q000276:immunology; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D013961:Thyroid Gland / Q000276:immunology*; D013997:Time Factors
chemical_list: D001323:Autoantibodies; C114753:CXCL10 protein, human; D054357:Chemokine CXCL10